Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer

NCT07457359 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

TNBC, Triple Negative Breast Cancer

Interventions

RADIATION: SBRT
DRUG: Toripalimab (anti-PD-1 antibody)
DRUG: Chemotherapy switch

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University